ರಕ್ತದ ಕ್ಯಾನ್ಸರ್ಗಳು
Leflunomide to Prevent Cytomegalovirus Reactivation in Stem Cell Transplant Patients
ಎಲ್ಲಿಗೆ ಹೋಗಬೇಕು
ಈ trial ಗೆ 1 ಆಸ್ಪತ್ರೆ ರೋಗಿಗಳನ್ನು ಸೇರಿಸಿಕೊಳ್ಳುತ್ತಿದೆ.
ರಿಜಿಸ್ಟ್ರಿ ಸಾರಾಂಶ (ತಾಂತ್ರಿಕ)
Patients undergoing half-matched hematopoietic stem cell transplantation (HSCT) are at high risk of viral reactivation after bone marrow transplantation (BMT). The purpose of this study is to evaluate whether leflunomide can prevent cytomegalovirus (CMV) reactivation in these patients and to assess its safety. The main questions it aims to answer are - 1. Does leflunomide prevent cytomegalovirus (CMV) related organ damage? 2. Does leflunomide prevent a rise in cytomegalovirus (CMV) copy number to more than 2000 copies/ml? 3. Does leflunomide prevent the need to start pre-emptive therapy for …
ಸ್ಪಾನ್ಸರ್: ಟಾಟಾ ಮೆಮೋರಿಯಲ್ ಸೆಂಟರ್
NCT07709013 on ClinicalTrials.gov
Last updated on the registry 16 Jul 2026 · read by us 20 Oct 2026